SHBC Overview

SHBC membership

Approximately 6,500 members drawn from all segments of the health sector, including:

  • Regional and national health plans
  • Insurance companies
  • Integrated delivery networks
  • Medicaid (state Medicaid and Medicaid managed care)
  • PBMs
  • Hospitals and health systems
  • Specialty pharmacy
  • Retail pharmacy
  • Long-term care
  • VA
  • Employers and researchers/consultants

Representative project recruitment segments

Primary recruitment for programs:

  • Private health plan medical and pharmacy directors and clinical pharmacists (directors of QA might be another target depending on program content): 4,100+
  • PBM medical and pharmacy directors: 914
  • Specialty pharmacy medical and pharmacy directors: 1,017
  • State Medicaid program medical and pharmacy directors and clinical pharmacists: 663
    • Consultants working with State Medicaid pharmacy programs: 42
    • Medicare FFS medical directors: 127
  • Case managers: 4,000 (health plans); 1,000 (hospitals)
Subtotal: 11,863

Secondary targets (depending on faculty and program interest) 

  • Self-funded employer directors of HR and directors of benefits: 9,768
  • Employer coalitions: 65
  • Employee benefit consultants: 412 
Subtotal: 10,245
Note: Total recruitment segments extend beyond SHBC members, which will be the first groups solicited. The additional targets are accessed through our market research partner. All participants will be subject to a detailed screener based on anticipated curriculum and recommendations of faculty.

Pharmacy & Therapeutics Society to SHBC evolution

  • PTS founded in 1999
  • Rebranded to SHBC in 2012 to emphasize transition to specialty pharmacy as an important component of health care
    • SHBC/PTS maintains activities in traditional pharma categories
  • Overall goal: Emphasize transition to specialty pharmacy, without giving up original mission and purpose; PTS is still an operating entity
  • PTS and SHBC will both be featured in upcoming programs and initiatives
  • SHBC recognizes and engages in activities relative to pharmaceutical care categories where even traditional, small molecule product costs may exceed $500 to $600 per month, thereby placing them on a “specialty tier” on many drug formularies

SHBC focus

  • Both high cost therapeutic categories (eg, oncology, HIV, hemophilia) and other categories that
    • Have complex or evolving treatment regimens
    • Offer new approaches to combination or adjunctive therapy
  • Categories where prior authorization and step therapy include both traditional and new therapies
  • Prior experience in categories such as HIV/AIDS
    • Payer advisory boards and webinar series
    • Multiple advisory boards of payer, employer, and advocacy organizations
    • Leadership of SHBC board members engaged in the issue

Web presence: present and future

  • Website www.SHBC.us currently under expansion
  • HIV and hemophilia programs posted with original CE materials for physicians, pharmacists, nurses, and case managers
  • Official Journal article links also posted
  • Plan for enhanced site includes expanded content and resources, and member/board exchanges on contemporary issues